PF-Atlas › Clinical Trials › NCT01426256
Vitamin D for Enhancing the Immune System in Cystic Fibrosis
Cholecalciferol · Phase 3
Registry ID
NCT01426256
Phase
Phase 3
Status
Completed
Drug / intervention
Cholecalciferol
Sponsor
Emory University
Start
2011-10
Enrollment
91
Locations
5
About this trial
The purpose of this study is determine if high-dose vitamin D supplementation improves clinical outcomes related to lung function and immunity in patients with Cystic Fibrosis who are admitted to the hospital with an acute lung infection.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01426256 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.